LGND – Ligand Pharmaceuticals Incorporated
LGND — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
9.81
Margin Of Safety %
-21
Put/Call OI Ratio
0.65
EPS Next Q Diff
0.95
EPS Last/This Y
2.76
EPS This/Next Y
2.86
Price
293.14
Target Price
343.8
Analyst Recom
1
Performance Q
Upside
-29.8%
Beta
1.15
Ticker: LGND
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | LGND | 309.09 | 0.72 | 0.73 | 1598 |
| 2026-07-14 | LGND | 300.51 | 0.73 | 0.28 | 1618 |
| 2026-07-15 | LGND | 295.39 | 0.72 | 0.21 | 1630 |
| 2026-07-16 | LGND | 296.57 | 0.73 | 1.75 | 1630 |
| 2026-07-17 | LGND | 303.51 | 0.65 | 0.67 | 1552 |
| 2026-07-20 | LGND | 294.15 | 0.58 | 0.17 | 1152 |
| 2026-07-21 | LGND | 305.36 | 0.58 | 0.83 | 1159 |
| 2026-07-22 | LGND | 304.13 | 0.58 | 999.99 | 1166 |
| 2026-07-23 | LGND | 302.21 | 0.59 | 2.60 | 1172 |
| 2026-07-24 | LGND | 300.04 | 0.58 | 0.17 | 1168 |
| 2026-07-27 | LGND | 297.41 | 0.58 | 1.64 | 1175 |
| 2026-07-28 | LGND | 296.49 | 0.59 | 1.54 | 1191 |
| 2026-07-29 | LGND | 288.08 | 0.63 | 0.23 | 1240 |
| 2026-07-30 | LGND | 296.29 | 0.62 | 1.57 | 1278 |
| 2026-07-31 | LGND | 287.8 | 0.63 | 5.00 | 1307 |
| 2026-08-03 | LGND | 292.02 | 0.66 | 0.89 | 1337 |
| 2026-08-04 | LGND | 301.19 | 0.67 | 0.40 | 1349 |
| 2026-08-05 | LGND | 302.73 | 0.67 | 0.26 | 1354 |
| 2026-08-06 | LGND | 300.74 | 0.65 | 0.48 | 1415 |
| 2026-08-07 | LGND | 292.15 | 0.65 | 0.20 | 1428 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | LGND | 308.95 | 24.4 | -28.2 | 9.10 |
| 2026-07-14 | LGND | 300.92 | 21.1 | -28.9 | 9.16 |
| 2026-07-15 | LGND | 295.60 | 21.1 | -27.3 | 9.16 |
| 2026-07-16 | LGND | 296.26 | 21.1 | -24.0 | 9.16 |
| 2026-07-17 | LGND | 303.66 | 19.8 | -20.3 | 9.16 |
| 2026-07-20 | LGND | 293.83 | 19.8 | -29.8 | 9.16 |
| 2026-07-21 | LGND | 305.36 | 19.8 | -17.6 | 9.16 |
| 2026-07-22 | LGND | 304.01 | 19.8 | -24.9 | 9.16 |
| 2026-07-23 | LGND | 302.20 | 19.8 | -25.4 | 9.16 |
| 2026-07-24 | LGND | 300.04 | 15.0 | -25.4 | 9.18 |
| 2026-07-27 | LGND | 297.08 | 15.0 | -26.2 | 9.18 |
| 2026-07-28 | LGND | 296.43 | 15.0 | -24.8 | 9.18 |
| 2026-07-29 | LGND | 288.18 | 15.0 | -29.2 | 9.18 |
| 2026-07-30 | LGND | 296.17 | 15.0 | -19.4 | 9.18 |
| 2026-07-31 | LGND | 287.54 | 15.0 | -29.3 | 9.18 |
| 2026-08-03 | LGND | 292.09 | 15.0 | -21.4 | 9.18 |
| 2026-08-04 | LGND | 292.09 | 15.0 | -21.4 | 9.18 |
| 2026-08-05 | LGND | 302.31 | 15.0 | -23.2 | 9.18 |
| 2026-08-06 | LGND | 300.74 | 15.0 | -25.1 | 9.18 |
| 2026-08-07 | LGND | 293.14 | 23.1 | -28.4 | 9.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | LGND | -12.20 | 1.41 | 10.85 |
| 2026-07-14 | LGND | -12.20 | 1.41 | 10.85 |
| 2026-07-15 | LGND | -12.20 | 1.41 | 10.85 |
| 2026-07-16 | LGND | -12.20 | 1.41 | 10.85 |
| 2026-07-17 | LGND | -12.20 | 1.41 | 10.85 |
| 2026-07-20 | LGND | -12.20 | 1.51 | 10.85 |
| 2026-07-21 | LGND | -12.20 | 1.51 | 10.85 |
| 2026-07-22 | LGND | -12.20 | 1.51 | 10.85 |
| 2026-07-23 | LGND | -12.20 | 1.51 | 10.85 |
| 2026-07-24 | LGND | -12.20 | 1.51 | 10.85 |
| 2026-07-27 | LGND | -12.20 | 1.69 | 9.81 |
| 2026-07-28 | LGND | -12.20 | 1.69 | 9.81 |
| 2026-07-29 | LGND | -12.20 | 1.69 | 9.81 |
| 2026-07-30 | LGND | -12.20 | 1.69 | 9.81 |
| 2026-07-31 | LGND | -12.20 | 1.69 | 9.81 |
| 2026-08-03 | LGND | -12.20 | 2.29 | 9.81 |
| 2026-08-04 | LGND | -12.20 | 2.29 | 9.81 |
| 2026-08-06 | LGND | -12.90 | 2.29 | 9.81 |
| 2026-08-07 | LGND | -12.90 | 2.29 | 9.81 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.63
Avg. EPS Est. Current Quarter
1.97
Avg. EPS Est. Next Quarter
2.58
Insider Transactions
-12.9
Institutional Transactions
2.29
Beta
1.15
Average Sales Estimate Current Quarter
63
Average Sales Estimate Next Quarter
80
Fair Value
232.09
Quality Score
96
Growth Score
77
Sentiment Score
70
Actual DrawDown %
10.3
Max Drawdown 5-Year %
-55.1
Target Price
343.8
P/E
31.35
Forward P/E
24.5
PEG
1.2
P/S
20.22
P/B
5.89
P/Free Cash Flow
47.73
EPS
9.35
Average EPS Est. Cur. Y
9.2
EPS Next Y. (Est.)
12.05
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
67.88
Relative Volume
0.81
Return on Equity vs Sector %
-11.9
Return on Equity vs Industry %
4.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.09
EBIT Estimation
-28.4
◆
LGND
Healthcare
$293.15
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
48.8
Range 1M
14.3%
Sup Dist
0.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
14.1%
52W%
80.6%
Long-Term Value
Quality companies, undervalued
WEAK
🔴 SELL
-7.6% upside
Upside
-7.6%
Quality
96
MoS
-21%
LGND — P/E HistoricalBiotechnology
Ligand Pharmaceuticals IncorporSector: Healthcare
Industry: Biotechnology
Employees: 47
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
LGND
Latest News
—
Caricamento notizie per LGND…
stock quote shares LGND – Ligand Pharmaceuticals Incorporated Stock Price stock today
news today LGND – Ligand Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch LGND – Ligand Pharmaceuticals Incorporated yahoo finance google finance
stock history LGND – Ligand Pharmaceuticals Incorporated invest stock market
stock prices LGND premarket after hours
ticker LGND fair value insiders trading